On Tuesday 26 March, the European Commission announced that it had opened its first formal investigation into a possible breach linked to exclusionary behaviour. It wants to determine whether the animal health company Zoetis (USA) prevented the market launch of a new medicine competing with Librela, a monoclonal antibody developed by Zoetis to treat pain associated with osteoarthritis in older dogs.
Zoetis acquired a product with a similar indication, which was at an advanced stage of...